search
Back to results

Enhanced Recovery After Surgery Program for Gastric Cancer: a Multi-center Study (ERASG1)

Primary Purpose

Gastric Cancer

Status
Unknown status
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
enhanced recovery after surgery
Sponsored by
Jinling Hospital, China
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Gastric Cancer focused on measuring enhanced recovery after surgery, gastric cancer

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Requirements of informed consent and assent of participant, parent or legal guardian as applicable
  2. Patients with gastric cancer scheduled for radical gastrectomy and between the age of 18 and 75 years old without considering sex
  3. ASA physical status I-III
  4. Participants can follow the drug doses and visit plan

Exclusion Criteria:

  1. Patients certified by a doctor that doesn't fit to participate in this study.
  2. Patients with ischemic heart disease, cerebrovascular disease and peripheral vascular disease, or their cardiac function > II (NYHA) patients, patients received CABG recently, and patients with severe hypertension (systolic pressure≥180mmHg or diastolic pressure≥110mmHg).
  3. Patients with gastric cancer with distant metastasis.
  4. Patients with severe infection, respiratory dysfunction, coagulation disorders, severe liver and renal dysfunction (Child - Pugh≥ 10; creatinine clearance < 25 ml/min).
  5. Patients allergic to common drugs, such as opioids, non-steroidal drugs, cephalosporins, etc.
  6. Patients with operations of gastrointestinal cancer and complicated abdominal operations.
  7. Patients complicated by gastric cancer with complications such as hemorrhage, perforation, obstruction.
  8. Patients with dyscrasia and severe malnutrition (albumin≤30g/L, weight loss in half a year>10%, SGA classification C, BMI<18, Hb<70g/L).
  9. Patients with metabolic complications caused by diabetes.
  10. Patients can't finish enhanced recovery after surgery programs and have contraindications of enhanced recovery after surgery.
  11. Pregnancy and lactation women, or have a pregnancy plan within a month after the test of the subjects (also including male participants).
  12. Patients participated other subjects 3 months before this subject.
  13. Sponsors or researchers directly involved in the testing or their family members.

Sites / Locations

  • The First People's Hospital of ChangzhouRecruiting
  • Changzhou Second People's Hospital Affiliated to Nanjing Medical UniversityRecruiting
  • The First People's Hospital of Lianyungang CityRecruiting
  • The Second People's Hospital of Lianyungang CityRecruiting
  • Jiangsu Cancer HospitalRecruiting
  • Nanjing First HospitalRecruiting
  • Jinling Hospital, Medical School of Nanjing UniversityRecruiting
  • Zhongda Hospital, Southeast UniversityRecruiting
  • the Second Affiliated Hospital of Nanjing Medical UniversityRecruiting
  • the First Affiliated Hospital of Nanjing Medical UniversityRecruiting
  • Suqian People's Hospital, Nanjing Drum Tower HospitalRecruiting
  • Suzhou Municipal HospitalRecruiting
  • The Second Affiliated Hospital of Soochow UniversityRecruiting
  • The First Affiliated Hospital of Soochow UniversityRecruiting
  • The First People's Hospital of TaicangRecruiting
  • Zhangjiagang First People's HospitalRecruiting
  • the Taizhou People's HospitalRecruiting
  • The 101 Hospital of the Chinese People's Liberation ArmyRecruiting
  • Affiliated Hospital of Jiangnan University, The Forth People's Hospital of Wuxi CityRecruiting
  • Xuzhou Central HospitalRecruiting
  • Northern Jiangsu People's HospitalRecruiting
  • Affiliated Hospital of Jiangsu UniversityRecruiting
  • Affiliated People's Hospital of Jiangsu UniversityRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

enhanced recovery after surgery

Arm Description

enhanced recovery after surgery includes: Multimodal analgesia Early oral intake A: Drink water after anesthetic awareness. B: Recover semi-liquid diet Management of nasogastric tube and catheter A: Not indwell nasogastric tube conventionally B: Remove catheter early Early activity Perioperative controlled infusion A: Load carbohydrate preoperatively B: No preoperative bowel preparation C: Fast six hours before surgery, no drink two hours before surgery D: Intraoperative liquid management: 3-6ml/kg/h, determined by anesthetists E: Stop intravenous infusion upon 2000-2500ml water and semiliquid diet being taken

Outcomes

Primary Outcome Measures

occurrence rate of severe complications
including death, anastomotic fistula, intra-abdominal hemorrhage, hemorrhage of digestive tract and complications need a reoperation

Secondary Outcome Measures

Occurrence rate of ordinary complications
Except severe complications, Clavien-Dindo classification ≥Ⅱ complications need not reoperation
Readmission rate within 30 days after discharge
Readmission rate within 30 days after discharge
Ideal postoperative length of hospital stay
reach discharge criteria
Actual postoperative length of hospital stay
Actual postoperative length of hospital stay
Operative time
Data of operation
Blood loss
Data of operation
Intraoperative infusion
Data of operation
TNM classification
Data of tumor
Number of dissected lymph node
Data of tumor
Time to first flatus
Bowel function recovery
Time to first defecation
Bowel function recovery
Time to first semi-liquid diet
Bowel function recovery
Time to first off-bed activity
Postoperative activity
Time of off-bed activity per day
Postoperative activity
Distance of off-bed activity per day
Postoperative activity
Postoperative pain
VAS classification
Hospital cost
Hospital cost
Management of catheters
including nasogastric tube, catheter, intraperitoneal drain, infusion tube
Preoperative length of hospital stay
Preoperative length of hospital stay
CD3+
Immune indicators
CD4+
Immune indicators
CD4+/CD8+
Immune indicators
IL-6
Inflammatory indicators
CRP
Inflammatory indicators
Albumin
Nutritional indicators
Prealbumin
Nutritional indicators
Transferrin
Nutritional indicators
Hb
Nutritional indicators
WBC
Nutritional indicators
PLT
Nutritional indicators
HCT
Nutritional indicators
Blood glucose
Nutritional indicators
Procalcitonin
Infectious indicator

Full Information

First Posted
April 13, 2017
Last Updated
April 27, 2018
Sponsor
Jinling Hospital, China
search

1. Study Identification

Unique Protocol Identification Number
NCT03121729
Brief Title
Enhanced Recovery After Surgery Program for Gastric Cancer: a Multi-center Study
Acronym
ERASG1
Official Title
Enhanced Recovery After Surgery Program for Gastric Cancer: a Multi-center Study
Study Type
Interventional

2. Study Status

Record Verification Date
April 2018
Overall Recruitment Status
Unknown status
Study Start Date
June 21, 2017 (Actual)
Primary Completion Date
August 31, 2018 (Anticipated)
Study Completion Date
December 2018 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Jinling Hospital, China

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study is aimed to evaluate the safety of applying enhanced recovery after surgery for gastric cancer.
Detailed Description
In China, gastric cancer results in the second highest morbidity and mortality rates among all malignancies. It is very important for treatment of gastric cancer to enhance the quality of treatment, increase patients' survival rate and improve the life quality. Now, "Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology" and "Japanese gastric cancer treatment guidelines 2014 (ver. 4)" recommended surgical resection for gastric cancer. As a result, increasing the quality of surgery and improving the perioperative measures have a great influence on patients received a gastrectomy. Before, patients discharged on 7-10 days after gastrectomy and recovered 4-8 weeks after surgery. So, it is significant for patients to recover from surgical trauma in order to receive other anti-cancer therapies after gastrectomy. Investigators spent over ten years studying enhanced recovery after surgery programs for gastric cancer and have got some successful experience. Investigators found enhanced recovery after surgery can accelerate patients' recovery without increasing complications. This study is the first multi-center study of enhanced recovery after surgery for gastric cancer all over the world. During this period, the study is aimed to evaluate the safety of applying enhanced recovery after surgery for gastric cancer.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gastric Cancer
Keywords
enhanced recovery after surgery, gastric cancer

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Patients will receive enhanced recovery after surgery programs.
Masking
None (Open Label)
Allocation
N/A
Enrollment
1000 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
enhanced recovery after surgery
Arm Type
Experimental
Arm Description
enhanced recovery after surgery includes: Multimodal analgesia Early oral intake A: Drink water after anesthetic awareness. B: Recover semi-liquid diet Management of nasogastric tube and catheter A: Not indwell nasogastric tube conventionally B: Remove catheter early Early activity Perioperative controlled infusion A: Load carbohydrate preoperatively B: No preoperative bowel preparation C: Fast six hours before surgery, no drink two hours before surgery D: Intraoperative liquid management: 3-6ml/kg/h, determined by anesthetists E: Stop intravenous infusion upon 2000-2500ml water and semiliquid diet being taken
Intervention Type
Procedure
Intervention Name(s)
enhanced recovery after surgery
Intervention Description
Undergo an enhanced recovery after surgery program
Primary Outcome Measure Information:
Title
occurrence rate of severe complications
Description
including death, anastomotic fistula, intra-abdominal hemorrhage, hemorrhage of digestive tract and complications need a reoperation
Time Frame
1 month
Secondary Outcome Measure Information:
Title
Occurrence rate of ordinary complications
Description
Except severe complications, Clavien-Dindo classification ≥Ⅱ complications need not reoperation
Time Frame
1 month
Title
Readmission rate within 30 days after discharge
Description
Readmission rate within 30 days after discharge
Time Frame
1 month
Title
Ideal postoperative length of hospital stay
Description
reach discharge criteria
Time Frame
1 month
Title
Actual postoperative length of hospital stay
Description
Actual postoperative length of hospital stay
Time Frame
1 month
Title
Operative time
Description
Data of operation
Time Frame
1 day
Title
Blood loss
Description
Data of operation
Time Frame
1 day
Title
Intraoperative infusion
Description
Data of operation
Time Frame
1 day
Title
TNM classification
Description
Data of tumor
Time Frame
1 week
Title
Number of dissected lymph node
Description
Data of tumor
Time Frame
1 week
Title
Time to first flatus
Description
Bowel function recovery
Time Frame
2 week
Title
Time to first defecation
Description
Bowel function recovery
Time Frame
2 week
Title
Time to first semi-liquid diet
Description
Bowel function recovery
Time Frame
2 week
Title
Time to first off-bed activity
Description
Postoperative activity
Time Frame
1 week
Title
Time of off-bed activity per day
Description
Postoperative activity
Time Frame
1 week
Title
Distance of off-bed activity per day
Description
Postoperative activity
Time Frame
1 week
Title
Postoperative pain
Description
VAS classification
Time Frame
1 week
Title
Hospital cost
Description
Hospital cost
Time Frame
1 month
Title
Management of catheters
Description
including nasogastric tube, catheter, intraperitoneal drain, infusion tube
Time Frame
1 month
Title
Preoperative length of hospital stay
Description
Preoperative length of hospital stay
Time Frame
1 month
Title
CD3+
Description
Immune indicators
Time Frame
1 week
Title
CD4+
Description
Immune indicators
Time Frame
1 week
Title
CD4+/CD8+
Description
Immune indicators
Time Frame
1 week
Title
IL-6
Description
Inflammatory indicators
Time Frame
1 week
Title
CRP
Description
Inflammatory indicators
Time Frame
1 week
Title
Albumin
Description
Nutritional indicators
Time Frame
1 week
Title
Prealbumin
Description
Nutritional indicators
Time Frame
1 week
Title
Transferrin
Description
Nutritional indicators
Time Frame
1 week
Title
Hb
Description
Nutritional indicators
Time Frame
1 week
Title
WBC
Description
Nutritional indicators
Time Frame
1 week
Title
PLT
Description
Nutritional indicators
Time Frame
1 week
Title
HCT
Description
Nutritional indicators
Time Frame
1 week
Title
Blood glucose
Description
Nutritional indicators
Time Frame
1 week
Title
Procalcitonin
Description
Infectious indicator
Time Frame
1 week

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Requirements of informed consent and assent of participant, parent or legal guardian as applicable Patients with gastric cancer scheduled for radical gastrectomy and between the age of 18 and 75 years old without considering sex ASA physical status I-III Participants can follow the drug doses and visit plan Exclusion Criteria: Patients certified by a doctor that doesn't fit to participate in this study. Patients with ischemic heart disease, cerebrovascular disease and peripheral vascular disease, or their cardiac function > II (NYHA) patients, patients received CABG recently, and patients with severe hypertension (systolic pressure≥180mmHg or diastolic pressure≥110mmHg). Patients with gastric cancer with distant metastasis. Patients with severe infection, respiratory dysfunction, coagulation disorders, severe liver and renal dysfunction (Child - Pugh≥ 10; creatinine clearance < 25 ml/min). Patients allergic to common drugs, such as opioids, non-steroidal drugs, cephalosporins, etc. Patients with operations of gastrointestinal cancer and complicated abdominal operations. Patients complicated by gastric cancer with complications such as hemorrhage, perforation, obstruction. Patients with dyscrasia and severe malnutrition (albumin≤30g/L, weight loss in half a year>10%, SGA classification C, BMI<18, Hb<70g/L). Patients with metabolic complications caused by diabetes. Patients can't finish enhanced recovery after surgery programs and have contraindications of enhanced recovery after surgery. Pregnancy and lactation women, or have a pregnancy plan within a month after the test of the subjects (also including male participants). Patients participated other subjects 3 months before this subject. Sponsors or researchers directly involved in the testing or their family members.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Zhi-Wei JIANG, Ph.D.
Phone
8602580860034
Email
nzjiangzhiwei@163.com
First Name & Middle Initial & Last Name or Official Title & Degree
Jian ZHAO, Ph.D.
Phone
8602580860034
Email
zhaojiangogo@163.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Zhi-Wei JIANG, Ph.D.
Organizational Affiliation
Jinling Hospital, Medical School of Nanjing University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Jian ZHAO, Ph.D.
Organizational Affiliation
Jinling Hospital, Medical School of Nanjing University
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Gang WANG, Ph.D.
Organizational Affiliation
Jinling Hospital, Medical School of Nanjing University
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Jiang LIU, M.D.
Organizational Affiliation
Jinling Hospital, Medical School of Nanjing University
Official's Role
Study Director
Facility Information:
Facility Name
The First People's Hospital of Changzhou
City
Changzhou
State/Province
Jiangsu
ZIP/Postal Code
213003
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Qicheng LU, M.D.
Email
changyiluqicheng@sina.com
First Name & Middle Initial & Last Name & Degree
Qicheng LU, M.D.
Facility Name
Changzhou Second People's Hospital Affiliated to Nanjing Medical University
City
Changzhou
State/Province
Jiangsu
ZIP/Postal Code
213164
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Liming TANG, M.D.
Email
drtanglm@gmail.com
First Name & Middle Initial & Last Name & Degree
Liming TANG, M.D.
Facility Name
The First People's Hospital of Lianyungang City
City
Lianyungang
State/Province
Jiangsu
ZIP/Postal Code
222002
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Huiyu CHEN, M.D.
First Name & Middle Initial & Last Name & Degree
Zengtao BAO, M.D.
First Name & Middle Initial & Last Name & Degree
Huiyu CHEN, M.D.
Facility Name
The Second People's Hospital of Lianyungang City
City
Lianyungang
State/Province
Jiangsu
ZIP/Postal Code
222006
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yongchang MIAO, M.D.
Email
lygmiao@sina.com
First Name & Middle Initial & Last Name & Degree
Gang WANG, M.D.
First Name & Middle Initial & Last Name & Degree
Yongchang MIAO, M.D.
Facility Name
Jiangsu Cancer Hospital
City
Nanjing
State/Province
Jiangsu
ZIP/Postal Code
210000
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gang LI, M.D.
Email
gang_lee@medmail.com.cn
First Name & Middle Initial & Last Name & Degree
Gang LI, M.D.
Facility Name
Nanjing First Hospital
City
Nanjing
State/Province
Jiangsu
ZIP/Postal Code
210000
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hongyong CAO, M.D.
Email
caohongy6167@163.com
First Name & Middle Initial & Last Name & Degree
Hongyong CAO, M.D.
Facility Name
Jinling Hospital, Medical School of Nanjing University
City
Nanjing
State/Province
Jiangsu
ZIP/Postal Code
210002
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Zhi-Wei JIANG, Ph.D.
Phone
8602580860034
Email
nzjiangzhiwei@163.com
First Name & Middle Initial & Last Name & Degree
Jian ZHAO, Ph.D.
Phone
8602580860034
Email
zhaojiangogo@163.com
First Name & Middle Initial & Last Name & Degree
Zhi-Wei JIANG, Ph.D.
First Name & Middle Initial & Last Name & Degree
Gang WANG, Ph.D.
First Name & Middle Initial & Last Name & Degree
Jian ZHAO, Ph.D.
First Name & Middle Initial & Last Name & Degree
Jiang LIU, M.D.
Facility Name
Zhongda Hospital, Southeast University
City
Nanjing
State/Province
Jiangsu
ZIP/Postal Code
210009
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jingmin WANG, M.D.
Email
wjm730222@163.com
First Name & Middle Initial & Last Name & Degree
Jingmin WANG, M.D.
Facility Name
the Second Affiliated Hospital of Nanjing Medical University
City
Nanjing
State/Province
Jiangsu
ZIP/Postal Code
210011
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jianping ZHANG, M.D.
Email
zhang_jp64@aliyun.com
First Name & Middle Initial & Last Name & Degree
Qinghong ZHAO, M.D.
Email
njzhqh@sina.com
First Name & Middle Initial & Last Name & Degree
Jianping ZHANG, M.D.
First Name & Middle Initial & Last Name & Degree
Qinghong ZHAO, M.D.
Facility Name
the First Affiliated Hospital of Nanjing Medical University
City
Nanjing
State/Province
Jiangsu
ZIP/Postal Code
210029
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lizong SHEN, M.D.
Email
shenlz@njmu.edu.cn
First Name & Middle Initial & Last Name & Degree
Yongbin DING, M.D.
First Name & Middle Initial & Last Name & Degree
Lizong SHEN, M.D.
Facility Name
Suqian People's Hospital, Nanjing Drum Tower Hospital
City
Suqian
State/Province
Jiangsu
ZIP/Postal Code
223800
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jianqiang WU, M.D.
Email
wjq-10@163.com
First Name & Middle Initial & Last Name & Degree
Jianqiang WU, M.D.
Facility Name
Suzhou Municipal Hospital
City
Suzhou
State/Province
Jiangsu
ZIP/Postal Code
215000
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Xinhua GU, M.D.
First Name & Middle Initial & Last Name & Degree
Renbin SHEN, M.D.
First Name & Middle Initial & Last Name & Degree
Xinhua GU, M.D.
Facility Name
The Second Affiliated Hospital of Soochow University
City
Suzhou
State/Province
Jiangsu
ZIP/Postal Code
215004
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Haorong WU, M.D.
Email
wuhaorong666@126.com
First Name & Middle Initial & Last Name & Degree
Yongyou WU, M.D.
Email
13338706607@126.com
First Name & Middle Initial & Last Name & Degree
Haorong WU, M.D.
First Name & Middle Initial & Last Name & Degree
Yongyou WU, M.D.
Facility Name
The First Affiliated Hospital of Soochow University
City
Suzhou
State/Province
Jiangsu
ZIP/Postal Code
215006
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Xinguo ZHU, M.D.
Email
zxg45@hotmail.com
First Name & Middle Initial & Last Name & Degree
Zhongqi MAO, M.D.
Email
maozq31@hotmail.com
First Name & Middle Initial & Last Name & Degree
Xinguo ZHU, M.D.
First Name & Middle Initial & Last Name & Degree
Zhongqi MAO, M.D.
Facility Name
The First People's Hospital of Taicang
City
Suzhou
State/Province
Jiangsu
ZIP/Postal Code
215400
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yi WANG, M.D.
First Name & Middle Initial & Last Name & Degree
Bing WANG, M.D.
First Name & Middle Initial & Last Name & Degree
Yi WANG, M.D.
Facility Name
Zhangjiagang First People's Hospital
City
Suzhou
State/Province
Jiangsu
ZIP/Postal Code
215600
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Shusheng WANG, M.D.
Email
Wsszyy2005@163.com
First Name & Middle Initial & Last Name & Degree
Shusheng WANG, M.D.
First Name & Middle Initial & Last Name & Degree
Liang ZHOU, M.D.
Facility Name
the Taizhou People's Hospital
City
Taizhou
State/Province
Jiangsu
ZIP/Postal Code
225300
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Qinghong LIU, M.D.
First Name & Middle Initial & Last Name & Degree
Honggang WANG, M.D.
First Name & Middle Initial & Last Name & Degree
Qinghong LIU, M.D.
Facility Name
The 101 Hospital of the Chinese People's Liberation Army
City
Wuxi
State/Province
Jiangsu
ZIP/Postal Code
214000
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Guozhong WU, M.D.
Email
jfj101hwugz@sina.cn
First Name & Middle Initial & Last Name & Degree
Guozhong WU, M.D.
Facility Name
Affiliated Hospital of Jiangnan University, The Forth People's Hospital of Wuxi City
City
Wuxi
State/Province
Jiangsu
ZIP/Postal Code
214062
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bojian FEI, M.D.
Email
wx4yfbj@163.com
First Name & Middle Initial & Last Name & Degree
Bojian FEI, M.D.
Facility Name
Xuzhou Central Hospital
City
Xuzhou
State/Province
Jiangsu
ZIP/Postal Code
221009
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Xiaopeng LV, M.D.
Email
18952171977@126.com
First Name & Middle Initial & Last Name & Degree
Xiaopeng LV, M.D.
Facility Name
Northern Jiangsu People's Hospital
City
Yangzhou
State/Province
Jiangsu
ZIP/Postal Code
225001
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ping CHEN, M.D.
Email
chen86ky@126.com
First Name & Middle Initial & Last Name & Degree
Xinxin LIU, M.D.
First Name & Middle Initial & Last Name & Degree
Ping CHEN, M.D.
First Name & Middle Initial & Last Name & Degree
Daorong WANG, M.D.
First Name & Middle Initial & Last Name & Degree
Xinxin LIU, M.D.
Facility Name
Affiliated Hospital of Jiangsu University
City
Zhenjiang
State/Province
Jiangsu
ZIP/Postal Code
212001
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jixiang CHEN, M.D.
Email
cyok9@163.com
First Name & Middle Initial & Last Name & Degree
Jixiang CHEN, M.D.
Facility Name
Affiliated People's Hospital of Jiangsu University
City
Zhenjiang
State/Province
Jiangsu
ZIP/Postal Code
212002
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Pengcheng JIANG, M.D.
Email
jpc18906106623@126.com
First Name & Middle Initial & Last Name & Degree
Shouliang ZHANG, M.D.
First Name & Middle Initial & Last Name & Degree
Pengcheng JIANG, M.D.

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Enhanced Recovery After Surgery Program for Gastric Cancer: a Multi-center Study

We'll reach out to this number within 24 hrs